Abstract
OBJECTIVE: We investigated whether REM sleep without atonia (RSWA) severity was associated with cognitive functioning in REM sleep behavior disorder (RBD). BACKGROUND: RBD is a potentially injurious parasomnia that is strongly associated with synucleinopathy. Patients with RBD exhibit RSWA, the loss of normal muscle atonia during REM sleep, on polysomnography (PSG). DESIGN/METHODS: Both idiopathic (iRBD) and symptomatic RBD (sRBD) patients completed two cognitive batteries: CNS Vital Signs (CNS-VS) and Useful Field of View (UFOV). All subjects underwent PSG and muscle (SM: submentalis; AT: anterior tibialis) tone during REM sleep was visually and automatically scored. Group differences between sRBD and iRBD were then compared, and regression models fit to determine the relationship of RSWA and dependent cognitive measures. RESULTS: Twenty iRBD and 10 sRBD participated. Demographics were similar between groups. Deficits on cognitive testing were observed on CNS-VS in processing (sRBD<iRBD, p=0.014) and psychomotor speed (sRDB<iRBD, p=0.019) and on Total UFOV and subtests 2 and 3 (sRBD>iRBD, all p<0.002). sRBD patients had greater combined phasic and tonic RSWA in SM (p=0.026) and longer mean phasic burst duration (p=0.03). Regression analyses demonstrated that SM RSWA independently predicted overall CNS-VS Neurocognitive Index (NCI) (F=4.5, p=0.006), adjusting for age, gender, depressive symptoms (Zung Score), and sleep disturbances (PSQI), and this relationship also remained significant for the iRBD group after excluding sRBD patients from analysis to account for the effect of co-morbid neurologic or cognitive disorders (F=3.5, p=0.03). SM RSWA was not predictive of total UFOV performance. CONCLUSIONS: RSWA is predictive of lower overall cognitive performance in patients with RBD. Future prospective analysis of a larger cohort is planned to determine whether RSWA may also predict other neurological signs of phenoconversion to overt synucleinopathy in iRBD patients. Study Supported by: UL1 RR024150-01.
Disclosure: Dr. Sandness has nothing to disclose. Dr. St. Louis has received personal compensation for activities with Inspire, Inc. Dr. McCarter has nothing to disclose. Dr. Boeve has received research support from GE Healthcare. Dr. Silber has nothing to disclose.
Thursday, April 23 2015, 2:00 pm-6:30 pm
- Copyright © 2015 by AAN Enterprises, Inc.
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan